Evidence map›Paper›PMID 39002005›Full record

Trial reportThe European journal of health economics : HEPAC : health economics in prevention and care2025

Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico.

Omar Galárraga, Marta Wilson-Barthes, Carlos Chivardi, Nathalie Gras-Allain, Fernando Alarid-Escudero, Monica Gandhi, Kenneth H Mayer, Don Operario

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The European journal of health economics : HEPAC : health economics in prevention and care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03674983 (PrEP Seguro), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03674983 nacompletednot on this map

PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico

TypeinterventionalSponsorBrown UniversityRan2019 to 2021Enrolled310ConditionsHIV InfectionsArmsConditional Economic Incentive (CEI)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omar GalárragaDepartment of Health Services Policy and Practice, Brown University School of Public Health, 121 South Main St. Box G-S121-2, Providence, RI, 02903, USA. omar_galarraga@brown.edu.ORCID http://orcid.org/0000-0002-9985-9266
Marta Wilson-BarthesInternational Health Institute, Brown University School of Public Health, 121 South Main St, Providence, RI, 02903, USA.
Carlos ChivardiNational Institute of Public Health (INSP), University No. 655 Colonia Santa María Ahuacatitlán, Cuernavaca, Mexico.
Nathalie Gras-AllainCenter for HIV/AIDS Prevention and Care, Clínica Especializada Condesa, Gral. Benjamín Hill 24, Hipódromo Condesa Cuauhtémoc, México City, 06170, Mexico.
Fernando Alarid-EscuderoCenter for Economics Teaching and Research (CIDE), Circuito Tecnopolo Norte #117, Col. Tecnopolo Pocitos II, Aguascalientes, CP, 20313, Mexico.
Monica GandhiUniversity of California, 1001 Potrero Ave, #423D, San Francisco, CA, 94110, USA.
Kenneth H MayerThe Fenway Institute, 7 Haviland St, Boston, MA, 02115, USA.
Don OperarioEmory University, 1518 Clifton Rd, Atlanta, GA, 30322, USA.

Funding

Science/Technical CoreP2CHD041020 · NICHD · BROWN UNIVERSITY · PI ZHENCHAO QIAN · 2016 to 2026
$7.6M
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6M
Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
PrEP Seguro: Antiretrovial-based HIV prevention among men at high risk in MexicoR34MH114664 · NIMH · BROWN UNIVERSITY · PI GALARRAGA, OMAR · 2017 to 2019
$638k
NIAID NIH HHS R01 AI098472NIAID NIH HHS R01 AI143340NIAID NIH HHS R37 AI098472NICHD NIH HHS P2C HD041020NIMH NIH HHS R34 MH114664U.S. National Institute of Allergy and Infectious Diseases 2RO1AI098472U.S. National Institute of Mental Health 5R34MH114664
6 · The paper itself

Abstract

Low adherence to preventative medications against life-long health conditions is a major contributor to global morbidity and mortality. We implemented a pilot randomized controlled trial in Mexico to measure the extent to which conditional economic incentives help male sex workers increase their adherence to pre-exposure prophylaxis (PrEP) for HIV prevention. We followed n = 110 male sex workers over 6 months. At each quarterly visit (at months 0, 3, and 6), all workers received a $10 transport reimbursement, a free 3-month PrEP supply, and completed socio-behavioral surveys. The primary outcome was an objective biomarker of medication adherence based on tenofovir (TFV) drug concentration levels in hair collected at each visit. Individuals randomized to the intervention received incentives based on a grading system as a function of PrEP adherence: those with high (> 0.043 ng/mg TFV concentration), medium (0.011 to 0.042 ng/mg), or low (< 0.011 ng/mg) adherence received $20, $10, or $0, respectively. Six-month pooled effects of incentives on PrEP adherence were analyzed using population-averaged gamma generalized estimating equation models. We estimated heterogeneous treatment effects by sex worker characteristics. The incentive intervention led to a 28.7% increase in hair antiretroviral concentration levels over 6 months consistent with increased PrEP adherence (p = 0.05). The effect of incentives on PrEP adherence was greater for male sex workers who were street-based (vs. internet) workers (p < 0.10). These pilot findings suggest that modest conditional economic incentives could be effective, at scale, for improving PrEP adherence among male sex workers, and should be tested in larger implementation trials. ClinicalTrials.gov Identifier: NCT03674983.

Indexed as

Anti-HIV AgentsHIV InfectionsMedication AdherenceMotivationPre-Exposure ProphylaxisSex WorkersAdultHairHumansMaleMexicoPilot ProjectsTenofovirYoung AdultAnti-HIV AgentsTenofovirAdherenceConditional economic incentivesHIV preventionMale sex workersPre-exposure prophylaxis (PrEP)

Identifiers

PMID39002005
PMCPMC11725604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.